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Abstract
Background: In social insurance, the evaluation of work disability is becoming stricter as priority is given to the
resumption of work, which calls for a guarantee of quality for these evaluations. Evidence-based guidelines have
become a major instrument in the quality control of health care, and the quality of these guidelines' development
can be assessed using the AGREE instrument. In social insurance medicine, such guidelines are relatively new. We
were interested to know what guidelines have been developed to support the medical evaluation of work
disability and the quality of these guidelines.
Methods: Five European countries that were reported to use guidelines were approached, using a recent
inventory of evaluations of work disability in Europe. We focused on guidelines that are disease-oriented and
formally prescribed in social insurance medicine. Using the AGREE instrument, these guidelines were appraised
by two researchers. We asked two experts involved in guideline development to indicate if they agreed with our
results and to provide explanations for insufficient scores.
Results: We found six German and sixteen Dutch sets of disease-oriented guidelines in official use. The AGREE
instrument was applicable, requiring minor adaptations. The appraisers reached consensus on all items. Each
guideline scored well on 'scope and purpose' and 'clarity and presentation'. The guidelines scored moderately on
'stakeholder involvement' in the Netherlands, but insufficiently in Germany, due mainly to the limited involvement
of patients' representatives in this country. All guidelines had low scores on 'rigour of development', which was
due partly to a lack of documentation and of existing evidence. 'Editorial independence' and 'applicability' had low
scores in both countries as a result of how the production was organised.
Conclusion: Disease-oriented guidelines in social insurance medicine for the evaluation of work disability are a
recent phenomenon, so far restricted to Germany and the Netherlands. The AGREE instrument is suitably
applicable to assess the quality of guideline development in social insurance medicine, but some of the scoring
rules need to be adapted to the context of social insurance. Existing guidelines do not meet the AGREE criteria
to a sufficient level. The way patients' representatives can be involved needs further discussion. The guidelines
would profit from more specific recommendations and, for providing evidence, more research is needed on the
functional capacity of people with disabilities.
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Background
In the western world, work disability is a problem at the
individual, company, and societal levels. Western coun-
tries spend about 1.2% of GDP on work disability benefits
or 2% if sickness benefits are included, which, for most
countries, is an increase over the past 15 years. The prob-
ability of returning to work after being granted a long-
term disability benefit is below 2% annually on average.
Work disability is the end of their working life for the vast
majority of recipients [1]. To reduce work disability, many
countries have restricted access to disability benefits in
social insurance and they have developed programmes to
promote return to work [2-4]. In the Netherlands, eligibil-
ity criteria have become stricter with the implementation
of a new law on long-term work disability. In the United
Kingdom, a renewal of the personal capacity assessment
for long-term disability benefit was recently implemented
[5] and comparable changes are occurring in other coun-
tries [2-4]. These policy changes are meant to result in
more people being active in work and fewer people receiv-
ing disability benefits. In disability benefit systems, social
insurance physicians (SIPs) evaluate claims for entitle-
ment to long-term disability benefits [6]. These work dis-
ability evaluations are traditionally based mainly on
legislation, administrative rules, and doctors' expertise.
When resources are tight, it becomes even more important
to determine in a valid and scientifically sound way who
is and is not entitled to disability benefit. Internationally,
the medical evaluations of work disability turn out to be
relatively comparable while being part of social insurance
systems that vary strongly [6-8]. The quality of these eval-
uations is not easy to establish, as no gold standard exists
for their validity [9,10]. The mechanism used most often
to ensure quality is to organise the process of evaluation
in such a way that an optimal result can be expected. A
common practice in 14 countries, in Europe and the Rus-
sian Federation, is to use qualified doctors, the SIPs, and
to have medical reports verified by staff doctors [6].
Although instruments used to support medical decision
making are not validated for this purpose [6,9,11], this
does not necessarily mean that they are unsuitable.
One way of ensuring the quality of medical work is to use
evidence-based guidelines [12], which is common in clin-
ical practice [13]. In clinical practice, guidelines, which
the clinician can use with his clinical experience and the
patient's preferences, are intended to support the physi-
cian by providing recommendations for diagnosis, treat-
ment, and prognosis. [14]. Evidence-based clinical
practice means using the best evidence available, in con-
sultation with the patient, to decide on the option that
suits that patient best [15]. Guidelines, however, are not
restricted to clinical practice: some are being introduced
on a wider scale in occupational medicine [16,17] and
serve, among other functions, to support the coaching of
employees with work-related health problems [18,19]. In
occupational medicine, guidelines are intended to pro-
vide an occupational physician with recommendations
for diagnosis and prognosis of the work-related problem
and for the selection of effective interventions [17]. These
guidelines can be used in addition to the experience of the
occupational health professional and the preferences of
the employee and employer. However, guidelines for
evaluation in social insurance medicine are a rather new
phenomenon.
Having guidelines for medical work does not necessarily
mean that the quality of the work is supported. Guidelines
need to be adequate for the process they are to support
and they need to be used in practice. The Appraisal of
Guidelines Research & Evaluation (AGREE) collaboration
developed the AGREE instrument to assess the quality of
clinical practice guidelines [20] and to establish the qual-
ity of the development of guidelines with regard to scien-
tific principles. The AGREE instrument is composed of
twenty-three items covering six domains of quality of
guideline development: 'scope and purpose', 'involve-
ment of stakeholders', 'rigour of development', 'clarity
and presentation of recommendations', 'applicability',
and 'editorial independence'. The AGREE instrument has
been tested in clinical guidelines and was found to have a
good reliability [21]. Thus far, there are no universally
accepted cut-off points to identify high-quality guidelines
[22]. A high-quality guideline can be expected to contrib-
ute to high-quality recommendations but does not war-
rant them as the evidence used is in general limited and
controversial [23,24]. The AGREE instrument is widely
used to evaluate clinical guidelines [25,26], as well as
those found in occupational medicine [16,27,28], but so
far has not been used in social insurance medicine. Social
insurance medicine may simply be lagging behind, but
the AGREE instrument may not be being used in social
insurance medicine because of the rather different medi-
cal work involved in social insurance.
Medical practice in social insurance evaluations is differ-
ent from clinical medical practice in several ways [29,30].
In clinical practice, the consultation is a private initiative
of a patient who seeks help that is often restricted by pol-
icies of health insurance, whereas in social insurance med-
icine the consultation is an evaluation that is determined
by the legal context and the constraints that the imple-
menting body, the Institution of Social Insurance (ISI),
puts on it. In clinical practice, the focus is on disease and
finding a cure, whereas in social insurance medicine the
focus is on capacity for, and a return to, work. In clinical
practice, a patient's request for treatment is taken for
granted; in social insurance medicine, the claim to be
exempt from work and for a benefit to be paid is scruti-BMC Public Health 2009, 9:349 http://www.biomedcentral.com/1471-2458/9/349
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nised and evaluated. The position of the claimant in a
social insurance context is therefore different from the
position of the patient in a clinical care context, differ-
ences that have been found to influence the practice of the
evaluations [31]. Furthermore, the position of social
insurance physicians is different from doctors in clinical
medicine as the SIPs have an advisory function towards
the ISI they work for and not primarily for the claimant
[6]. This position may give rise to tensions between
administrative procedures for handling big numbers of
claimants and the doctors' need to deliver tailor-made
evaluations [32,33].
It is difficult to diagnose the functional consequences of
diseases in general and even more so for non-specific dis-
eases such as lower back pain, chronic fatigue, and stress-
related disorders. The association between a medical diag-
nosis and the functional limitations that may lead to work
disability is weak and influenced by environmental and
personal characteristics, as described in the International
Classification of Functioning and Health (ICF) model
[34]. From a legal standpoint, evaluations of work disabil-
ity become more difficult due to stricter eligibility criteria
with respect to objectivity, diagnosis, and prognosis of the
disability. Sound support from evidence-based guidelines
would, therefore, be welcome. The European Union of
Medicine in Assurance and Social Security (EUMASS), a
network of insurance medicine associations in seventeen
European countries, recently published a comparison of
work disability evaluation practices and the instruments
in use, including guidelines [8]. This comparison was pro-
duced by several questionnaire rounds among central
medical staff of participating countries. Two central ques-
tions in that study were
1. What is evaluated in your countries' work disability
evaluation?
2. What instruments are used for these evaluations?
We were interested to determine what guidelines exist in
different countries and their quality by focusing on the
following research questions:
1. What disease-oriented guidelines have been developed to
support the medical evaluation of work disability?
2. What is the quality of these guidelines in social insur-
ance medicine?
Methods
1. Identification of disease-oriented guidelines to evaluate 
work disability
We used the EUMASS table to determine the countries in
which guidelines were reported to be in use. The Nether-
lands, the Czech Republic, Germany, the United King-
dom, and Switzerland were visited based on their reported
use of the guidelines; no other countries had reported
using guidelines for medical evaluations. The status of
guidelines was assessed during the visits by determining if
they were officially prescribed. Copies of the guidelines
with explanation were collected. For this article we
focused on the guidelines for evaluating work disability
by SIPs that were prescribed by law or as an instruction by
the ISI. We distinguished between disease-oriented guide-
lines (describing aspects of evaluations for certain pathol-
ogies) and process-oriented guidelines (describing aspects
of evaluations, regardless of pathology), a distinction that
is evident from the relative guideline's title. We selected
disease-oriented guidelines. To compare guidelines, we
selected those that addressed the same diseases.
2. Quality appraisal of guidelines
The selected guidelines were scored using the AGREE
instrument, which uses 4-point scales for each item: scope
and purpose (3 items), stakeholder involvement (4
items), rigour of development (7 items), clarity and pres-
entation of the recommendations (4 items), applicability
of the guideline (3 items), and editorial independence (2
items). To correct for the different number of items in
each domain, The AGREE instruments suggests calculat-
ing domain scores by relating the obtained scores (OS) to
the maximum possible score (MaPS) and the minimum
possible score (MiPS) using the formula
As a test, one (Dutch) guideline (burnout) was scored by
two researchers (WdB and DB) using the AGREE instru-
ment and its user guide to establish if additional rules for
scoring would be required. The test showed the need for
additional scoring rules. We specified the clinical question
and the target population and we adapted user guide item
11 (health benefits, side effects and risks) and 16 (options
for management of the condition) [see Additional File 1].
The selected guidelines were then scored independently
by two researchers (WdB and DB). The initial agreement
between the researchers was determined using Kappa. Any
differences were discussed, but if a difference remained, a
decisive third researcher (JRA) would score as well, using
the scores and arguments of the first two. We analysed the
initial correlation between the two scoring researchers. As
this use of the AGREE instrument is new in social insur-
ance medicine, we asked one expert in each country who
had participated in developing several guidelines for a
reaction to our results: "Are these correct in your view and
what is your explanation for any insufficient scores?"
OS-MiPS MaPS-MiPS /BMC Public Health 2009, 9:349 http://www.biomedcentral.com/1471-2458/9/349
Page 4 of 9
(page number not for citation purposes)
Ethics committee
This study was not submitted for ethical approval. The
study included physicians who were not asked to perform
specific professional actions for this study, but only to
complete a questionnaire. All studied documents are in
the public domain.
Results
1. Identification of disease-oriented guidelines to evaluate 
work disability
In Germany seven guidelines for SIPs turned out to be
officially in use. In the Netherlands twenty-four were
found and one in Switzerland. These guidelines are partly
process-oriented and partly disease-oriented. Process
guidelines were used in Germany (1), the Netherlands
(8), and Switzerland (1). The German and Swiss guide-
lines each contain many recommendations that in the
Netherlands are distributed over eight smaller guidelines.
The recommendations refer, for example, to the relevance
of the diagnosis for the evaluation and to the boundaries
of the concept of disease. Another topic of these guide-
lines is the claimant's obligation to attempt to recover and
find gainful employment. Yet another aspect is the rele-
vance of distinguishing between the opinions of the
claimant and the SIP. These recommendations represent
the consensus of legal and medical experts on the princi-
ples of evaluation, but not on scientific evidence. These
process-oriented guidelines were excluded.
Disease-oriented guidelines were in use in Germany (6)
and the Netherlands (16), shown in Table 1. In the Czech
Republic, a Barema-type of guideline is in official use, but
this was excluded from this study as it evaluates impair-
ments, not work disability.
The Dutch guidelines, all implemented by law, were first
developed by the Health Council of the Netherlands and
later by the scientific association of SIPs (NVVG). The Ger-
man guidelines were developed and prescribed by the
German Institution of Social Insurance (DRV). The Ger-
man guidelines were developed earlier than the Dutch
and most have been updated since their inception.
2a. The appraisal of quality with the AGREE instrument of 
selected guidelines
Of the guidelines, four diseases were common to both
countries: breast cancer, chronic obstructive lung disease,
lumbar intervertebral disc herniation, and myocardial inf-
arction.
The initial agreement between researchers was high for the
Dutch guidelines (Kappa range 0.814-0.939), but low for
the German counterparts (Kappa range 0.449-0.624).
After discussing the different opinions of the researchers,
agreement was reached on all items and scoring by the
third researcher was unnecessary. The results are pre-
sented in Table 2.
The scope and purpose of the guideline were well described in
all eight guidelines; the score in both countries was 100%.
All guidelines were designed to support the medical eval-
uation of work disability by indicating what functional
incapacities were to be expected in cases with a specific
diagnosis.
Stakeholder involvement was 52% for the Dutch and 33%
for the German guidelines. Potential users were well
defined (social insurance physicians), but the involve-
ment of professional groups was found to be incomplete
in seven of the eight guidelines. The patients' views were
not sought in the German guidelines and only at the final
stage in the Dutch. No guidelines were piloted among
end-users before their publication.
Rigour of development was 16% with the Dutch and 23%
with the German guidelines. How evidence was gathered
and the scientific grounding of recommendations were
not explicit in any guideline.
Clarity and presentation of the guidelines was 63% for the
Dutch guidelines and 71% for the German. Although the
recommendations were unambiguous and easily identifi-
able in almost all cases, they were not overly specific. Dif-
ferent options for assessing the condition of the
guidelines were often mentioned, and the German guide-
lines provided tools for the evaluations.
Applicability scored 6% in the Netherlands and 8% in Ger-
many. Practical barriers and costs were not addressed in
any guideline. The German guidelines contained indica-
tions of when to update them.
Editorial independence was limited in both countries. The
Dutch guidelines reached 50% on average as they were
developed independently of the funding body, but with
only a general procedure about conflicting interests. The
German guidelines (0%) were developed entirely within
the ISI and conflicting interests were not addressed.
2b Feedback on the AGREE scores by experts involved in 
developing several guidelines
The Dutch expert was involved in developing 11 of 16
then-published guidelines in the Netherlands and 3 of the
4 protocols that we scored on the AGREE instrument. He
agreed to all our scoring after we discussed our scoring
rules with him. He attributed low scores to the newness of
creating guidelines for social insurance medicine in the
Netherlands and that the short time allotted to create
them was a factor. Stakeholder involvement was also
reduced because patients' involvement was controversialBMC Public Health 2009, 9:349 http://www.biomedcentral.com/1471-2458/9/349
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in the beginning as there was concern about patients
being biased with regard to the recommendations. The
low figure on rigour of development was because the
methods of development had not been recorded and
because the field had no scientific tradition. The lack of
specificity of the recommendations was due mainly to a
lack of existing scientific research. Applicability scored
low in the Netherlands as the guidelines were developed
by the Health Council, for whom this was not a regular
activity. The aspects of applicability were considered by
the ISI after publication of the guidelines.
Table 1: Diagnosis-oriented guidelines for SIPs to country, publisher, and year of publication/revision, nr of pages (exc summary and 
addenda) and nr of references.
Guideline (country and publisher) Year Pages References
Aspecific Lumbar Disorder (NL, Health Council) 2005/2008 20 15
Myocardial Infarction (NL, Health Council) 2005/2008 22 45
Anxiety Disorders (NL, Health Council) 2007 30 27
Stroke (NL, Health Council) 2007 30 30
Breast Cancer (NL, Health Council) 2007 24 35
Chronic Fatigue Syndrome (NL, Health Council) 2007 26 22
Herniating Intervertebral Disc (NL, Health Council) 2007 20 14
Burnout (NL, Health Council) 2007 28 29
Depressive Disorder (NL, Health Council) 2007 32 29
Whiplash Associated Disorders (NL, Health Council) 2008 26 24
Arthritis Hip and Knee (NL, NVVG) 2007 28 56
Rheumatoid Arthritis (NL, NVVG) 2007 34 57
Chronic Obstructive Lung Disease (NL, NVVG) 2007 46 54
Chronic Heart Failure (NL, NVVG) 2007 30 41
Schizophrenia and associated psychoses (NVVG) 2007 50 135
Chronic Shoulder Disorders (NL, NVVG) 2007 21 37
Mental disorders (DE, DRV) 2001/2006 53 59
Herniating Intervertebral Disc (DE, DRV) 2002/2003/2005 26 28
Chronic Inflammatory Bowel Disease (DE, DRV) 2005 26 60
Coronary Heart Disease (DE, DRV) 2001/2005 20 54
Chronic Obstructive Lung Disease (DE, DRV) 2003/2005 34 47
Breast Cancer (DE, DRV) 2006 22 42BMC Public Health 2009, 9:349 http://www.biomedcentral.com/1471-2458/9/349
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The German expert was involved in developing five of six
guidelines published at the time in Germany and in all the
guidelines we scored on the AGREE instrument. He agreed
to nineteen of the twenty-three scores after we discussed
our scoring rules with him. Differences were due partly to
how the German guidelines were described (experts
involved were not identified with their specialisation) and
to differences in the interpretation of items 13, 14, and 15.
He commented that the development of guidelines was
new in Germany and started from a need of the SIPs
within the ISI, which explained the limited involvement
of stakeholders. The involvement of patients' representa-
tives was considered unhelpful because of expected bias.
Testing among users was done implicitly as the guidelines
were developed at the institution where the SIPs work.
The selection of evidence and formulation of recommen-
dations were carried out according to what the German
experts considered the most important. No need had
existed to document any more than they did for internal
use, which accounted for the low score on the rigour of
the guidelines' development. This internal development
also accounted for the low score on applicability; this was
included implicitly within the development process of
internal guidelines. Editorial independence was not con-
sidered important, as the interests of the SIPs and the ISI
were not supposed to conflict.
Discussion
In this study we looked for the existence of evidence-based
guidelines for the medical evaluation of long-term work
disability and the quality of development of these guide-
lines.
Main findings
Using the EUMASS comparison, we found guidelines for
the medical evaluation of work disability, both disease-
and process-oriented, in official use in four of seventeen
European countries. In two of these countries we found
twenty-two disease-oriented guidelines in official use in
these evaluations. The AGREE instrument was applicable
for scoring the selected Dutch and German guidelines,
although minor adaptations to the AGREE instrument
were necessary. Scoring German guidelines gave a smaller
initial agreement than the Dutch, due to language prob-
lems and understanding of the German social insurance;
however, the consensus procedure compensated for these
issues. The guidelines scored well on 'scope and purpose'
and 'clarity and presentation', and moderately on 'stake-
holder involvement' in the Netherlands, but low in Ger-
many; all guidelines scored low on 'rigour of
development'. 'Editorial independence' and 'applicability'
were low as a result of how production was organised.
Strengths and weaknesses
To our knowledge, this is the first study to identify and
qualify medical guidelines in social insurance medicine at
an international level. As we were looking for official
guidelines, we do not believe that we missed any in the
countries we included; however, focusing on official
guidelines may have resulted in finding fewer guidelines
than are in practical use. For example, in Germany and
Switzerland, guidelines are published by specialists in sci-
entific journals. These are not in official use, but they may
support physicians in their evaluations.
Table 2: AGREE scores of selected guidelines to domain
Breast Cancer Chronic Obstructive 
Lung Disease
Lumbar Intervertebral 
Disc Herniation
Myocardial Infarction Total
Dutch German Dutch German Dutch German Dutch German Dutch German
Scope and 
purpose of the 
guideline
100 100 100 100 100 100 100 100 100 100
Stakeholder 
involvement
58 33 50 33 50 33 50 33 52 33
Rigour of 
development
10 19 19 24 19 19 14 29 16 23
Clarity and 
presentation
75 67 75 67 50 75 50 75 63 71
Applicability 11 0 11 33 0 0 0 0 6 8
Editorial 
independence
50 0 50 0 50 0 50 0 50 0BMC Public Health 2009, 9:349 http://www.biomedcentral.com/1471-2458/9/349
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We used the AGREE instrument to determine the quality
of the guidelines, which recommends using four apprais-
ers for a good reliability [20]. Using a pilot procedure and
two researchers for scoring, we obtained good agreement,
which was supported by the opinion of the two experts
who were involved in developing the guidelines. All items
of the AGREE instrument proved to be relevant for testing
the guidelines. We did not encounter important aspects
that were not addressed by the AGREE instrument; further
validation is needed however. Our adaptations are partly
specifications of the scope of the AGREE instrument to the
context of social insurance medicine, but are unlikely to
influence the integrity of the AGREE instrument. Our
adaptations of items 11 and 16 are less clear-cut transla-
tions that need to be tested.
Other studies
Our study corresponds with other research; the distinc-
tion between legal and medical guidelines fits with the
results of Boer et al. [35] about the medical and legal
aspects of a doctor's reasoning. The reliability of the
AGREE instrument outside the clinical domain [16,27,28]
was partly confirmed in our study, after minor alterations
were made. Finding that guidelines do not fully meet the
AGREE criteria is not uncommon [22,36-38], partly due
to the lack of a precise account of the development proc-
ess and partly because of a lack of scientific evidence; both
are not uncommon problems in drafting guidelines
[22,39,40]. The relative lack of scientific research on the
work participation of people with chronic diseases is also
well documented [40-43].
Impact
We found disease-oriented guidelines in only two partici-
pating countries, and there they are recent. Work disabil-
ity is being evaluated on similar aspects in many
countries, despite large differences in organisation of
social insurance [6]; thus, we expect the development of
guidelines to be likely elsewhere. Our results may be help-
ful in facilitating this.
Our comparison of development quality is based on four
Dutch and four German guidelines, on four different
pathologies. The German and Dutch social insurance sys-
tems differ in many aspects, but both require a medical
statement about functional capacity in cases of claims for
work disability benefit. From this perspective the guide-
lines are comparable in and between countries. As the
guidelines in these countries have been created in a simi-
lar fashion, we expect our results to be relevant to future
disease-oriented guideline development in these coun-
tries.
We used the AGREE instrument as a tool for evaluating
the quality of guideline development in social insurance
medicine, a procedure that, to our knowledge, is new. It is
unclear if using the AGREE instrument in a different
domain is without problems; however, neither we, nor
the experts we consulted, noticed any clear incongruence.
The AGREE instrument is now being utilised in both Ger-
many and the Netherlands.
With the AGREE instrument the quality of the develop-
ment of guidelines can be scored, which is not the same as
the quality of the recommendations. It is possible that the
guidelines contain adequate recommendations that have
been developed in a suboptimal way or whose develop-
ment has been accounted for in a suboptimal way. Good
practice, however, is best supported by guidelines that
have been developed in a proven, optimal way. Several
aspects need further consideration. The involvement of
patients' representatives is now accepted in the Nether-
lands, after much discussion about the nature of their
input; in Germany, however, this is not the case. This dif-
ference illustrates the ambiguity of the claimant's position
in social insurance medicine: he is both passive object of
the evaluation and participating subject in work disabil-
ity. AGREE criteria are clear, however: participation of
patients' representatives is mandatory. The development
of the guidelines in the Netherlands has now been placed
under the authority of the scientific association of SIPs, as
this is viewed as the best way to retain independence from
both the funding and implementing bodies. In Germany,
financing, developing, and implementing within the ISI is
considered effective, which illustrates the ambiguity of the
profession of social insurance medicine as a discipline
that needs to stress its independence and quality and a
group of doctors working for administrative organisms
with more interests than medical quality [29,33]. AGREE
criteria are clear on this aspect, too: a good guideline
needs to be developed independently.
The inclusion of disease-oriented research into the prac-
tice of disability evaluation will help coordinate clinical,
occupational, and social insurance medicine, in using the
same concepts and findings, although in different spheres.
The lack of scientific evidence may be compensated for, in
part, by research on the aspects that influence disability
with chronic conditions in general [41,43]. Parallel to
this, research needs to be commenced to establish if the
guidelines actually contribute to quality improvement.
Finally, the production of these guidelines will help for-
mulate the questions that need to be addressed in future
research to ground social insurance evaluations.
We expect that the diffusion of our results may aid further
development of guidelines in social insurance medicine
and, notably, help these become increasingly more evi-
dence-based, which would assist in establishing a new
and important mechanism for quality control in socialBMC Public Health 2009, 9:349 http://www.biomedcentral.com/1471-2458/9/349
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insurance medicine. Paraphrasing Lohr [15], evidence-
based evaluation practice in social insurance medicine
would mean using the best evidence available and the best
procedure possible to decide on the option that suits that
claimant best.
Conclusion
Evidence-based guidelines form an important instrument
for enhancing the quality of medical practice. Guidelines
can provide a framework on which a clinician can ground
diagnosis, therapy, and prognosis. Guidelines in social
insurance medicine for the evaluation of work disability
are a recent phenomenon, so far restricted to Germany
and the Netherlands. We expect that disease-oriented
guidelines can be useful in other countries as well, and
can help the SIP ground his evaluation of capacity for
work. For the practice of evaluating work disability, this
would mean an important instrument to control quality.
The AGREE instrument is suitably applicable for assessing
the quality of guideline development in social insurance;
nevertheless, some of the scoring rules need to be adapted
to the context of social insurance. Existing guidelines do
not meet AGREE criteria sufficiently. Notably, how
patients' representatives can be involved and the editorial
independence of the guideline developers need further
discussion. The guidelines would profit from more spe-
cific recommendations and, for this, more research is
needed on the functional capacity of people with disabil-
ities. To date, research has focused primarily on the recov-
ery from complaints, while mainly ignoring the
resumption of work. The latter depends on much more
than a health condition, but still, the challenge of health
care should not only be to give relief for pain and suffer-
ing, but also to allow participation in society and to legit-
imise a disability benefit if needed for medical reasons.
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